Literature DB >> 26927288

Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population.

C-C Chang1, C-C Ng2, C-L Too3, S-E Choon4, C-K Lee5, W-H Chung6, S H Hussein1, K-S Lim7, S Murad3.   

Abstract

Phenytoin (PHT) is a common cause of severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS). Although HLA-B*15:02 is associated with PHT-induced SJS/TEN (PHT-SJS/TEN) in Han Chinese and Thais, the genetic basis for susceptibility to PHT-induced SCARs (PHT-SCAR) in other populations remains unclear. We performed a case-control association study by genotyping the human leukocyte antigen (HLA)-B alleles of 16 Malay PHT-SCAR patients (13 SJS/TEN and 3 DRESS), 32 PHT-tolerant controls and 300 healthy ethnicity-matched controls. A novel genetic biomarker, HLA-B*15:13, showed significant association with PHT-SJS/TEN (53.8%, 7/13 cases) (odds ratio (OR) 11.28, P=0.003) and PHT-DRESS (100%, 3/3 cases) (OR 59.00, P=0.003) when compared with PHT-tolerant controls (9.4%, 3/32 controls). We also confirmed HLA-B*15:02 association with PHT-SJS/TEN (61.5%, 8/13 cases vs 21.9%, 7/32 controls; OR 5.71, P=0.016) when compared with PHT-tolerant controls. These alleles may serve as markers to predict PHT-SCAR in Malays.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26927288     DOI: 10.1038/tpj.2016.10

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  29 in total

1.  Medical genetics: a marker for Stevens-Johnson syndrome.

Authors:  Wen-Hung Chung; Shuen-Iu Hung; Hong-Shang Hong; Mo-Song Hsih; Li-Cheng Yang; Hsin-Chun Ho; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal:  Nature       Date:  2004-04-01       Impact factor: 49.962

2.  Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?

Authors:  S H Kardaun; A Sidoroff; L Valeyrie-Allanore; S Halevy; B B Davidovici; M Mockenhaupt; J C Roujeau
Journal:  Br J Dermatol       Date:  2007-03       Impact factor: 9.302

3.  HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain.

Authors:  Kongkiat Kulkantrakorn; Wichittra Tassaneeyakul; Somsak Tiamkao; Thawinee Jantararoungtong; Napat Prabmechai; Suda Vannaprasaht; Pansu Chumworathayi; Pei Chen; Paskorn Sritipsukho
Journal:  Pain Pract       Date:  2011-06-16       Impact factor: 3.183

4.  Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions.

Authors:  B Rzany; O Correia; J P Kelly; L Naldi; A Auquier; R Stern
Journal:  Lancet       Date:  1999-06-26       Impact factor: 79.321

5.  Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans.

Authors:  Sae-Hoon Kim; Kyung Wha Lee; Woo-Jung Song; Sang-Heon Kim; Young-Koo Jee; Sang-Min Lee; Hye-Ryun Kang; Heung-Woo Park; Sang-Heon Cho; Seong-Ho Park; Kyung-Up Min; Yoon-Seok Chang
Journal:  Epilepsy Res       Date:  2011-09-13       Impact factor: 3.045

6.  Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.

Authors:  Wen Yi Ding; Chew Kek Lee; Siew Eng Choon
Journal:  Int J Dermatol       Date:  2010-07       Impact factor: 2.736

7.  Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese.

Authors:  Shuen-Iu Hung; Wen-Hung Chung; Zhi-Sheng Liu; Chien-Hsiun Chen; Mo-Song Hsih; Rosaline Chung-yee Hui; Chia-Yu Chu; Yuan-Tsong Chen
Journal:  Pharmacogenomics       Date:  2010-03       Impact factor: 2.533

8.  Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population.

Authors:  Choong-Chor Chang; Chun-Lai Too; Shahnaz Murad; Suraiya Hani Hussein
Journal:  Int J Dermatol       Date:  2011-02       Impact factor: 2.736

9.  HLA-B*15 subtypes in Burmese population by sequence-based typing.

Authors:  C Kongmaroeng; A Romphruk; R Ruangwerayut; C Paupairoj; C Leelayuwat; H Inoko; A Romphruk
Journal:  Tissue Antigens       Date:  2009-06-02

10.  Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations.

Authors:  Faviel F Gonzalez-Galarza; Stephen Christmas; Derek Middleton; Andrew R Jones
Journal:  Nucleic Acids Res       Date:  2010-11-09       Impact factor: 16.971

View more
  26 in total

Review 1.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

2.  High and variable population prevalence of HLA-B*56:02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptoms.

Authors:  Andrew A Somogyi; Daniel T Barratt; Elizabeth J Phillips; Kylies Moore; Fahmida Ilyas; Genevieve M Gabb
Journal:  Br J Clin Pharmacol       Date:  2019-07-19       Impact factor: 4.335

Review 3.  Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS)/Drug-Induced Hypersensitivity Syndrome (DiHS)-Readdressing the DReSS.

Authors:  Hannah Stirton; Neil H Shear; Roni P Dodiuk-Gad
Journal:  Biomedicines       Date:  2022-04-26

4.  Treatment of severe drug reactions by hemodialysis.

Authors:  Rokea A El-Azhary; Michael Z Wang; Ashley B Wentworth; LaTonya J Hickson
Journal:  Int J Dermatol       Date:  2017-11-22       Impact factor: 2.736

Review 5.  The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions.

Authors:  Patricia T Illing; Anthony W Purcell; James McCluskey
Journal:  Immunogenetics       Date:  2017-07-10       Impact factor: 3.330

Review 6.  Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention.

Authors:  Kalliopi Gerogianni; Aspasia Tsezou; Konstantinos Dimas
Journal:  Mol Diagn Ther       Date:  2018-06       Impact factor: 4.476

Review 7.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

Review 8.  Severe Delayed Drug Reactions: Role of Genetics and Viral Infections.

Authors:  Rebecca Pavlos; Katie D White; Celestine Wanjalla; Simon A Mallal; Elizabeth J Phillips
Journal:  Immunol Allergy Clin North Am       Date:  2017-11       Impact factor: 3.479

Review 9.  Genetic Determinants in HLA and Cytochrome P450 Genes in the Risk of Aromatic Antiepileptic-Induced Severe Cutaneous Adverse Reactions.

Authors:  Ali Fadhel Ahmed; Chonlaphat Sukasem; Majeed Arsheed Sabbah; Nur Fadhlina Musa; Dzul Azri Mohamed Noor; Nur Aizati Athirah Daud
Journal:  J Pers Med       Date:  2021-05-07

Review 10.  Genetics of Severe Cutaneous Adverse Reactions.

Authors:  Shang-Chen Yang; Chun-Bing Chen; Mao-Ying Lin; Zhi-Yang Zhang; Xiao-Yan Jia; Ming Huang; Ya-Fen Zou; Wen-Hung Chung
Journal:  Front Med (Lausanne)       Date:  2021-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.